(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 10.36% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.9%.
Phibro Animal Health's revenue in 2025 is $1,190,682,000.On average, 3 Wall Street analysts forecast PAHC's revenue for 2026 to be $57,087,290,306, with the lowest PAHC revenue forecast at $53,539,221,463, and the highest PAHC revenue forecast at $59,517,928,643.
In 2027, PAHC is forecast to generate $58,785,891,682 in revenue, with the lowest revenue forecast at $55,524,557,583 and the highest revenue forecast at $61,102,792,716.